Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
Bioorg Chem ; 114: 104970, 2021 09.
Artigo em Inglês | MEDLINE | ID: mdl-34120026

RESUMO

Thiazolidinediones (TZD), benzopyrans are the proven scaffolds for inhibiting Aldose reductase (ALR2) activity and their structural confluence with the retention of necessary fragments helped in designing a series of hybrid compounds 2-(5-cycloalkylidene-2,4-dioxothiazolidin-3-yl)-N-(2-oxo-2H-chromen-3-yl)acetamide (10a-n) for better ALR2 inhibition. The compounds were synthesized by treating substituted 3-(N-bromoacetyl amino)coumarins (9a-d) with potassium salt of 5-cyclo alkylidene-1,3-thiazolidine-2,4-diones (4a-d). The inhibition activity against ALR2 with IC50 values range from 0.012 ± 0.001 to 0.056 ± 0.007 µM. N-[(6-Bromo-3-coumarinyl)-2-(5-cyclopentylidene-2,4-dioxothiazolidin-3-yl)] acetamide (10c) with cyclopentylidene group on one end and the 6-bromo group on the other end showed better inhibitory property (IC50 = 0.012 µM) and selectivity index (324.166) against the ALR2, a forty fold superiority over sorbinil, a better molecule over epalrestat and rest of the analogues exhibited a far superior response over sorbinil and slightly better as compared with epalrestat. It was further confirmed by the insilico studies that compound 10c showed best inhibition activity among the synthesized compounds with a high selectivity index against the ALR2. In invivo experiments, supplementation of compound 10c to STZ induced rats delayed the progression of cataract in a dose-dependent manner warranting its further development as a potential agent to treat thediabetic secondary complications especially cataract.


Assuntos
Aldeído Redutase/antagonistas & inibidores , Cumarínicos/uso terapêutico , Diabetes Mellitus Experimental/tratamento farmacológico , Inibidores Enzimáticos/uso terapêutico , Hipoglicemiantes/uso terapêutico , Tiazolidinedionas/uso terapêutico , Aldeído Redutase/metabolismo , Animais , Catarata/prevenção & controle , Cumarínicos/síntese química , Cumarínicos/metabolismo , Cumarínicos/farmacocinética , Desenho de Fármacos , Inibidores Enzimáticos/síntese química , Inibidores Enzimáticos/metabolismo , Inibidores Enzimáticos/farmacocinética , Hipoglicemiantes/síntese química , Hipoglicemiantes/metabolismo , Hipoglicemiantes/farmacocinética , Masculino , Simulação de Acoplamento Molecular , Estrutura Molecular , Ligação Proteica , Ratos Sprague-Dawley , Relação Estrutura-Atividade , Tiazolidinedionas/síntese química , Tiazolidinedionas/metabolismo , Tiazolidinedionas/farmacocinética
2.
J Mol Graph Model ; 33: 61-76, 2012 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-22182469

RESUMO

Genetic engineering of Bacillus thuringiensis (Bt) Cry proteins has resulted in the synthesis of various novel toxin proteins with enhanced insecticidal activity and specificity towards different insect pests. In this study, a fusion protein consisting of the DI-DII domains of Cry1Ac and garlic lectin (ASAL) has been designed in silico by replacing the DIII domain of Cry1Ac with ASAL. The binding interface between the DI-DII domains of Cry1Ac and lectin has been identified using protein-protein docking studies. Free energy of binding calculations and interaction profiles between the Cry1Ac and lectin domains confirmed the stability of fusion protein. A total of 18 hydrogen bonds was observed in the DI-DII-lectin fusion protein compared to 11 hydrogen bonds in the Cry1Ac (DI-DII-DIII) protein. Molecular mechanics/Poisson-Boltzmann (generalized-Born) surface area [MM/PB (GB) SA] methods were used for predicting free energy of interactions of the fusion proteins. Protein-protein docking studies based on the number of hydrogen bonds, hydrophobic interactions, aromatic-aromatic, aromatic-sulphur, cation-pi interactions and binding energy of Cry1Ac/fusion proteins with the aminopeptidase N (APN) of Manduca sexta rationalised the higher binding affinity of the fusion protein with the APN receptor compared to that of the Cry1Ac-APN complex, as predicted by ZDOCK, Rosetta and ClusPro analysis. The molecular binding interface between the fusion protein and the APN receptor is well packed, analogously to that of the Cry1Ac-APN complex. These findings offer scope for the design and development of customized fusion molecules for improved pest management in crop plants.


Assuntos
Proteínas de Bactérias/química , Antígenos CD13/química , Endotoxinas/química , Proteínas Hemolisinas/química , Lectinas/química , Manduca/enzimologia , Proteínas Recombinantes de Fusão/química , Proteínas Recombinantes de Fusão/metabolismo , Sequência de Aminoácidos , Animais , Toxinas de Bacillus thuringiensis , Proteínas de Bactérias/metabolismo , Sítios de Ligação , Antígenos CD13/metabolismo , Endotoxinas/metabolismo , Alho/química , Proteínas Hemolisinas/metabolismo , Ligação de Hidrogênio , Proteínas de Insetos/química , Proteínas de Insetos/metabolismo , Lectinas/metabolismo , Modelos Moleculares , Simulação de Dinâmica Molecular , Dados de Sequência Molecular , Conformação Proteica , Engenharia de Proteínas , Estrutura Terciária de Proteína
3.
J Med Chem ; 54(8): 2902-14, 2011 Apr 28.
Artigo em Inglês | MEDLINE | ID: mdl-21443194

RESUMO

Herein, we discovered a series of propynoic acid carbamoyl methyl-amides (PACMAs) with potent cytotoxicity against a panel of cancer cell lines. These compounds interrupted cell cycle progression at low micromolar concentrations and induced early and late stage apoptosis. A representative compound suppressed tumor growth without apparent toxicity in an MDA-MB-435 mouse xenograft model. We used a Kinexus 628-antibody microarray and the Ingenuity Pathway Analysis (IPA) bioinformatics tools to better understand their mechanisms. The IPA analysis revealed the initiation of Nrf2-mediated oxidative stress through modulating the expression of SOD1 and STIP1 by compound 1. The involvement of the oxidative stress pathway was further validated by measuring the levels of the PACMA-induced mitochondrial superoxide species. To our knowledge, this is the first report on the discovery and biological evaluations of PACMAs as anticancer agents. Their broad-spectrum in vitro cytotoxicity, possibly through an oxidative stress-mediated pathway, and in vivo efficacy warrant further preclinical investigations.


Assuntos
Alcinos/farmacologia , Amidas/química , Antineoplásicos/farmacologia , Descoberta de Drogas , Propionatos/farmacologia , Alcinos/química , Alcinos/farmacocinética , Animais , Antineoplásicos/química , Antineoplásicos/farmacocinética , Apoptose/efeitos dos fármacos , Caspase 9/efeitos dos fármacos , Divisão Celular/efeitos dos fármacos , Linhagem Celular Tumoral , Avaliação Pré-Clínica de Medicamentos , Humanos , Espectroscopia de Ressonância Magnética , Camundongos , Estresse Oxidativo , Propionatos/química , Propionatos/farmacocinética , Proteína Supressora de Tumor p53/efeitos dos fármacos , Ensaios Antitumorais Modelo de Xenoenxerto
4.
J Mol Graph Model ; 29(2): 256-65, 2010 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-20727800

RESUMO

Bacillus anthracis is a causative organism of anthrax. The main reason to use anthrax as a bioweapon is the combination of the spore's durability and the lethal toxaemia of the vegetative stage. In anthrax infection, lethal factor (LF) is playing crucial role in causing cell death, by inhibiting pathways that rely on this kinase family. The combination of vaccine and antibiotics is preferred as an effective treatment for this target. Till date, no small molecule inhibitor is identified as a drug on the target. In this study, we have performed pharmacophore modeling and docking studies to identify a novel small molecule inhibitor to target the Anthrax LF. The best pharmacophore model is used to screen approximately 2M drug-like small molecule database and yielded 2543 hits. Docking studies of the pharmacophore hits on to the active site of Anthrax LF resulted 120 structurally diverse hits. Out of 120 hits, based on synthetic feasibility, 17 hits are selected for further synthesis and pharmacological screening. In due course, we will publish the updated results.


Assuntos
Antitoxinas/química , Antitoxinas/farmacologia , Toxinas Bacterianas/antagonistas & inibidores , Desenho de Fármacos , Avaliação Pré-Clínica de Medicamentos , Modelos Moleculares , Interface Usuário-Computador , Antígenos de Bactérias/química , Toxinas Bacterianas/química , Domínio Catalítico , Cristalografia por Raios X , Ligantes , Conformação Molecular
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA